Taisho Pharmaceutical Holdings Co., Ltd.
4581
Rangering i aksjer
#3722
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Aksjekurs
$54.31
Sist synkronisert: 2024-04-08
Markedsverdi
$4.45B
Endring (1 dag)
-4.14%
Endring (1 år)
0.00%
Land
JP
Handel Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Kategori
Healthcare
Driftsmargin for Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Driftsmargin per October 2026 TTM: 7.64%
Ifølge Taisho Pharmaceutical Holdings Co., Ltd. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 7.64%. Ved slutten av 2022 hadde selskapet en driftsmargin på 4.01%.
Historikk for driftsmargin for Taisho Pharmaceutical Holdings Co., Ltd. fra 2006 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | 7.64% | 0.00% |
| 2023 | 7.64% | 90.52% |
| 2022 | 4.01% | -43.36% |
| 2021 | 7.08% | -4.71% |
| 2020 | 7.43% | -37.77% |
| 2019 | 11.94% | -9.55% |
| 2018 | 13.20% | 15.49% |
| 2017 | 11.43% | 14.76% |
| 2016 | 9.96% | -9.54% |
| 2015 | 11.01% | -21.80% |
| 2014 | 14.08% | 13.64% |
| 2013 | 12.39% | -12.50% |
| 2012 | 14.16% | -13.71% |
| 2011 | 16.41% | 22.28% |
| 2010 | 13.42% | -9.32% |
| 2009 | 14.80% | -19.30% |
| 2008 | 18.34% | 35.75% |
| 2007 | 13.51% | -37.31% |
| 2006 | 21.55% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 10.52% | -98.62% |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -97.00% |
IN
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.